PCOL 310 Flashcards
Federal Food, Drug, and Cosmetic Act of 1938
-Required manufacturers demonstrate safety of new drugs prior to marketing
-Allowed FDA to inspect manufacturing facilities
-Defined the following key terms: drug, device, cosmetics and labeling
Durham-Humphrey Amendment of 1951
distinguishes prescription from non-prescription
Kefauver-Harris Amendment of 1962
-required that manufacturers prove the effectiveness of drug products before they go on the market, and report any serious side effects
-required that evidence of effectiveness be based on adequate and well-controlled clinical studies conducted by qualified experts
-gave FDA 180 days to approve a new drug application
Orphan Drug Act of 1983
-drugs intended to treat rare diseases and conditions
-provides pharmaceutical manufacturers tax and licensing incentives to develop them
food
- articles used for food or drink for man or other animals
- chewing gum
- articles used for components of any such article.
drug
- Articles recognized in the official USP/NF or Homeopathic Pharmacopoeia, or any supplement to any of them
- Articles intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease in man or other animals
- Articles other than food intended to affect the structure or function of the body of man or other animals
(no destinction b/w prescription vs. non-prescription & human vs. animal)
Waxman Hatch Amendment of 1984-
Drug price Competition and patent term restoration act
-Streamlined generic drug approval process to make them more readily available
-created certain market and patent exclusivity periods for both branded and generic drug companies
Labeling
All labels and other written, printed, or graphic matter on any container or wrapper or material accompanying the product
-Package insert
-drug advertisement
-information in publications ( PDR)
-Promotional materials such as newsletter and literature
GMP
Good manufacturing practice
-Applies to manufacturers, not pharmacies
-Drugs subject to GMP are selected based on medical importance,market share, number of similar products in the marketplace, and previous compliance record of the manufacturer.
- Every two years manufacturers must register with the FDA to be inspected.
Non prescription drug labeling
-Display panel
-Must have detailed usage and warning info so consumers can properly choose and use the products
Principal Display Panel
-Panel of the label that is most likely to be displayed, presented, shown or examined by the end user
Commercial Container Label
for the health care professional and not the consumer
Drug listing act of 1972
Required manufacturers to provide the FDA with a current list of all drugs manufactured, prepared, propagated,compounded, or processed by it for commercial distribution
NDC code
1234-5678-90
1234= manufacturer
5678=drug
90=package
Seizure
The physical isolation of a drug while FDA or state agency files civil lawsuit
-What drugs can the FDA seize?
-Mis branded or adulterated
Recall
- The correction or removal, and notification to the company, of a product that is in violation of the law.
-3 levels of recall
cosmetic
Articles intended to be rubbed, poured, sprinkled or sprayed on, introduced into , or otherwise applied on the human body, or any part thereof for cleansing, or altering the appearance.
-Articles intended for use as a component in any such articles, not including soap
Dietary Supplement
A product taken by mouth that is intended to supplement the diet and contains one or more dietary ingredients, Including
-Vitamins
-Minerals
-Herbs or other botanicals
-amino acids
-other substances found in the human diet such as enzymes
-Must be labeled as such and must not be represented as conventional food or as the sole item of a meal of the diet
-Conventional foods are foods that are not dietary supplements (Nutrition facts vs supplement facts panel)
Device
An instrument, apparatus, machine, contrivance, implant, in vitro Reagent, or other similar or related article, including any part component or accessory intended to diagnose or treat a disease
label
display of written material on the products container or on the outside container or wrapper
class 1
reasonable probability that the use of, or exposure too a violative product will cause serious adverse health consequences or death
class 2
Use of or exposure too may cause a temporary or medically reviserable adverse health consequence,or where the probability of serious health consequences is remote.
class 3
Use or exposure to the product is not likely to cause serious adverse health consequences
IND
Investigational New drug application
-Evaluated by: Office of new drugs (OND) & Center for Drug Evaluation and Research (CDER)
Institutional Review Board (IRB)
-“Pay to Play”
-Support timely review
-Options for waivers/reduction/refunds
-Applicable for small businesses, first time applicants
Risk Evaluation and Mitigation Strategies (REMS)
-FDA can require REMS for certain medications with serious safety concerns to ensure benefits outweigh the risks
Standard FDA review path
12 months
Priority FDA review path
8 months
-Demonstrate that the drug or biologic has potential to significantly improve safety of effectiveness of treatment, diagnosis, prevention of serious/life threatening conditions
-FDA has 60 days to review an NDA
Abbreviated New Drug Application
-Process where generic products are approved after expiration of patent held by innovator company
-Requires proof that generic’s pharmacokinetics, bioavailability and clinical activity are similar to the innovator product
Supplemental new drug application SNDA
-Submitted after the NDA approval
- Covers change in synthesis, production procedures, manufacturing locations, indications
Agencies responsible for drug advertising
-FDA regulates prescription drug advertising
-Federal Trade Commission: regulates non prescription drugs under the federal trade commission act
Non clinical testing objectives
Does compound or molecule work
How can we deliver it to the right cell/tissues/ organs
Is it safe
Can we manufacture it ensuring safety, practicality, stability
Types of Non clinical trial studies
In Vitro- Controlled enviornment outside living organism
In Vivo- Using a whole, live living organism
In Silicio- on a computer
Pharmacodynamics studies
method of action vs mode of action
Mechanism
Biochemical interaction through which a drug substance produces a pharmacological effect
Mode
describes functional or anatomical changes at the cellular level resulting from the exposure of a living organism to a substance- action on specific receptors or enzymes
Pharmacokinetic studies
Determine the highest and lowest concentration in the body after med administration, movement of drugs within the body
ADME
absorption, distribution, metabolism, excretion
Good Laboratory Practice
The batches of the active ingredient must be qualified and produced according to the GMP guidelines
CMC
Chemistry, manufacturing and control. Term used in the context of production and quality control of drugs or drug candidates.
Non-clinical outcomes that can STOP development
-Discovery of organ toxicity
-Identification of poor pharmacokinetic properties
IACUC
Institutional Animal Care and Use committee.
-must review all animal experiment protocols
AAALAC
Association for assessment and accreditation of laboratory animal care
-Non-profit organization that accredits research facilities for compliance with the guide